Revvity Inc vs Materials Select Sector SPDR Fund — how do they compare? Revvity Inc trades at $154.18 (market cap $16.98B), while Materials Select Sector SPDR Fund trades at $49.43 (market cap $7.73B). The key difference: Revvity Inc is far larger — about 2.2× Materials Select Sector SPDR Fund's market cap, and Revvity Inc pays a 0.18% dividend while Materials Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Materials Select Sector SPDR Fund for 70 Days on average.
| RVTY | XLB | |
|---|---|---|
Market Cap | $16.98B | $7.73B |
Volume | 1,456,900 | 13,681,146 |
Sector | Health | — |
52-Week High | $157.36 | $53.67 |
52-Week Low | $82.26 | $42.23 |
Typical Hold Time | 12 Days | 70 Days |
Enterprise Value | $19.30B | — |
Dividend Yield | 0.18% | — |
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
XLB trades at $49.27 with a slight 0.59% daily gain, though technical indicators signal bearish momentum with moving averages and ADX pointing lower. The materials ETF faces headwinds from sector concentration risks, with chemicals comprising 49% of assets and top 10 holdings at 59% exposure. Recent analysis suggests much of the cyclical recovery appears priced in, limiting near-term upside potential despite infrastructure and manufacturing tailwinds.
The outlook remains cautious with technical weakness outweighing fundamental support. Investment opportunity exists in long-term materials exposure through efficient, low-cost ETF structure, but risks include sector concentration, cyclical pressures, and competition from AI-focused investments. Current levels near key support at $48-$49 require monitoring for potential breakdown.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →